You are here: Industry Insights > antibody

News List

AbCellera Collaborates with Autolus on Antibody Discovery Project pharmafocusasia
November 30, 2018
AbCellera announced today its collaboration with Autolus Therapeutics plc (Autolus), a clinical stage biopharmaceutical company developing next-generation programmed T cell therapies.....
Charles River and Distributed Bio Enter Exclusive Partnership pharmafocusasia
November 28, 2018
Charles River Laboratories International, Inc today announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platforms.....
HiFiBiO Therapeutics Signs Multi-Target Antibody Discovery Agreement with Takeda pharmafocusasia
November 27, 2018
HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis, today announced...
Eisai announces Data from the Phase II Clinical Trial of BAN2401 biospectrumasia
October 29, 2018
Clinical Study 201 is a placebo-controlled, double-blind, parallel-group, randomized study in 856 patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) with confirmed amyloid pathology in the brain
In clinical trials, new antibody therapy controls HIV for months after treatment worldpharmanews
September 29, 2018
To remain healthy, people infected with HIV must therefore adhere to strict medication regimens, which typically involve ingesting pills every day for the rest of their lives.
Antibody combo controls HIV for months fiercebiotech
September 28, 2018
New clinical trials from Rockefeller University researchers suggest that a combination of two anti-HIV antibodies is capable of suppressing HIV for months.
Alexion to acquire Syntimmune biospectrum
September 27, 2018
The deal gives Alexion clinical-stage anti-FcRn antibody SYNT001 with potential to address a number of rare IgG-mediated diseases
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project cphi-online
July 25, 2018
Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.
Novartis pays €95M to bag dermatitis drug from Galapagos, MorphoSys fiercebiotech
July 23, 2018
Novartis is set to pay €95 million ($110 million) upfront for the global rights to Galapagos and MorphoSys’ anti-IL-17C antibody MOR106.
Organ-chips model and predict thrombotic side effect caused by anti-CD154 antibody europeanpharmaceuticalreview
May 07, 2018
An Emulate, Inc. study has demonstrated that its Blood Vessel-Chip accurately modelled and predicted thrombosis, or clotting of blood, induced by certain monoclonal antibody drugs, specifically anti-CD154 monoclonal antibody (mAb) hu5c8.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page